Case Report: Cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy

Abstract

We present the case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma (cSCC) of the sternal area, which was not amenable to radiation therapy. The treatment history of this patient is remarkable as the disease had progressed through all lines of conventional therapy established in the literature. We decided to initiate treatment with epidermal growth factor receptor (EGFR) inhibitor cetuximab and we reassessed the patient after 12 weeks with a whole-body CT scan, documenting stability in the size and radiologic features of the disease. Cetuximab, like all current treatments for advanced cSCC, is administered off-label and proved effective in preventing further progression of disease in our patient.

Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma

“…Intervention Cutaneous Basaloid Squamous Cell Carcinomas [45] Combined Systemic and Intratumoral Administration of Human Papillomavirus Vaccine Advanced cutaneous squamous cell carcinoma resistant to chemotherapy [46] Cetuximab Advanced non-resectable cutaneous squamous cell carcinoma [47] Pembrolizumab and concurrent hypo-fractionated radiotherapy Advanced rare cancers including cSCC [48] Pembrolizumab…”